undamentalytics Newsletter
Sign in

Coya Therapeutics, Inc. income statement

In fiscal 2025, Coya Therapeutics, Inc. reported revenue of $7.9m, up 123.6% on the year before, operating income of −$22.6m (a -283.9% margin) and net income of −$21.2m, or −$1.27 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue06488
Research and development46121717
General and administrative5891112
Operating income−10−8−17−23−23
Income before tax−12−7−16−21—
Income tax01−10—
Net income−12−8−15−21−22
Diluted EPS−$1.18−$0.79−$0.98−$1.27−$1.09
Diluted shares (average)10m10m15m17m20m
EBITDA−10−8−17−23−23

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ACRS vs COYAADAG vs COYAAPLM vs COYA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Coya Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Coya Therapeutics, Inc.